| ACR20 | ACR50 | ||
---|---|---|---|---|
Dose of tofacitinib | Sample size (tofacitinib, adalimumab) | Risk ratio [95% CI] | Sample size (tofacitinib, adalimumab) | Risk ratio [95% CI] |
Month 3 | Â | Â | Â | Â |
1Â mg bid | 54, 53 | 0.88 [0.52, 1.50] | 54, 53 | 0.59 [0.23, 1.51] |
3Â mg bid | 51, 53 | 1.09 [0.67, 1.80] | 51, 53 | 1.25 [0.59, 2.63] |
5Â mg bid | 49, 53 | 1.65 [1.08, 2.53] | 49, 53 | 1.95 [1.00, 3.80] |
10Â mg bid | 61, 53 | 1.97 [1.32, 2.92] | 61, 53 | 2.35 [1.26, 4.38] |
15Â mg bid | 57, 53 | 2.01 [1.35, 2.98] | 57, 53 | 2.70 [1.46, 4.98] |
Month 6, | Â | Â | Â | Â |
5Â mg bid | 196, 199 | 1.09 [0.89, 1.33] | N/A | N/A |
10Â mg bid | 196: 199 | 1.11 [0.91, 1.36] | N/A | N/A |